ethyl [(1,3-benzothiazol-2-ylmethyl)amino]acetate | 1016645-21-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl [(1,3-benzothiazol-2-ylmethyl)amino]acetate
• 英文别名: ethyl 2-(1,3-benzothiazol-2-ylmethylamino)acetate
• CAS: 1016645-21-8
• 化学式: C₁₂H₁₄N₂O₂S
• mdl: MFCD13207432
• 分子量: 250.321
• InChiKey: XPDRWFYXXRIMFH-UHFFFAOYSA-N

物化性质

• 沸点：
  367.8±27.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(3-甲氧基苯基)-4-甲基-1,3-恶唑-5-羧酸 、 ethyl [(1,3-benzothiazol-2-ylmethyl)amino]acetate 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以75%的产率得到ethyl ((1,3-benzothiazol-2-ylmethyl){[2-(3-methoxyphenyl)-4-methyl-1,3-oxazol-5-yl]carbonyl}amino)acetate
  参考文献：
  名称：

  Towards Gram-negative antivirulence drugs: New inhibitors of HldE kinase

  摘要：

  Gram-negative bacteria lacking heptoses in their lipopolysaccharide (LPS) display attenuated virulence and increased sensitivity to human serum and to some antibiotics. Thus inhibition of bacterial heptose synthesis represents an attractive target for the development of new antibacterial agents. HldE is a bifunctional enzyme involved in the synthesis of bacterial heptoses. Development of a biochemical assay suitable for high-throughput screening allowed the discovery of inhibitors 1 and 2 of HldE kinase. Study of the structure-activity relationship of this series of inhibitors led to highly potent compounds. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.021
• 作为产物：
  描述：

  1,3-苯并噻唑-2-甲胺盐酸盐 、 氯乙酸乙酯 在 三乙胺 作用下， 以 乙腈 为溶剂， 以58%的产率得到ethyl [(1,3-benzothiazol-2-ylmethyl)amino]acetate
  参考文献：
  名称：

  New 1,2,4-triazine derivatives and biological applications thereof

  摘要：

  这项发明涉及公式(I)的新1,2,4-三嗪衍生物： 其中A、B、R2和Y在申请中有定义， 它们的制备和中间体，它们作为药物和药物组合物的用途以及含有它们的关联物。 公式(I)的化合物能够抑制细菌七糖合成。

  公开号：

  EP2141164A1

文献信息

• Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
  申请人：Escaich Sonia

  公开号：US20100022541A1

  公开（公告）日：2010-01-28

  The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR 1 , C1-C10 alkyl-NR 1 R 1 , alkoxy, hydroxy, thioalkyl, aryl, heterocycle, halogen, nitro, cyano, CO 2 R 1 , NR 1 R 1 , NR 1 C(O)R 1 , C(O)NR 1 R 1 , NR 1 C(S)R 1 , C(S)NR 1 R 1 , SO 2 NR 1 R 1 , SO 2 R 1 , NR 1 SO 2 R 1 , NR 1 C(O)NR 1 R 1 , NR 1 C(O)OR 1 , NR 1 C(S)NR 1 R 1 , NR 1 C(S)OR 1 , R 1 C═NOR 1 , C(O)R 1 , aryloxy, thioaryl, alkenyl, alkynyl R1 identical or different is H or C1-C10 alkyl B 1 , B 2 , B 3 identical or not represent C, N, O, S to form a five-membered aromatic ring wherein from one to three carbon atoms are replaced by a heteroatom selected from S, O, N optionally substituted by one or several identical or different R such as defined above B 4 is C or N Y is H, C1-C10 alkyl, alkoxy, thio-alkyl, optionally substituted by one or several identical or different R such as defined above W is C, O or N, substituted or not by one or several C1-C10 alkyl radicals D is an heterocycle optionally substituted by one or several identical or different R such as defined above.

  本发明涉及具有抑制庚糖合成特性的新化合物，其具有式(I)或其药学上可接受的盐或前药，其中A为芳基或杂环，任选地被一个或多个相同或不同的R取代，如H、C1-C10烷基、C1-C10烷基-OR1、C1-C10烷基-NR1R1、烷氧基、羟基、硫代烷基、芳基、杂环、卤素、硝基、氰基、CO2R1、NR1R1、NR1C(O)R1、C(O)NR1R1、NR1C(S)R1、C(S)NR1R1、SO2NR1R1、SO2R1、NR1SO2R1、NR1C(O)NR1R1、NR1C(O)OR1、NR1C(S)NR1R1、NR1C(S)OR1、R1C═NOR1、C(O)R1、芳氧基、硫代芳基、烯基、炔基，R1相同或不同为H或C1-C10烷基；B1、B2、B3相同或不同，代表C、N、O、S以形成五元芳香环，其中一到三个碳原子被选自S、O、N的杂原子替换，任选地被一个或多个相同或不同的如上定义的R取代；B4为C或N；Y为H、C1-C10烷基、烷氧基、硫代烷基，任选地被一个或多个相同或不同的如上定义的R取代；W为C、O或N，被或不被一个或多个C1-C10烷基基团取代；D为任选地被一个或多个相同或不同的如上定义的R取代的杂环。
• Novel HldE-K Inhibitors Leading to Attenuated Gram Negative Bacterial Virulence
  作者：Nicolas Desroy、Alexis Denis、Chrystelle Oliveira、Dmytro Atamanyuk、Sophia Briet、Fabien Faivre、Géraldine LeFralliec、Yannick Bonvin、Mayalen Oxoby、Sonia Escaich、Stéphanie Floquet、Elodie Drocourt、Vanida Vongsouthi、Lionel Durant、François Moreau、Theodore B. Verhey、Ting-Wai Lee、Murray S. Junop、Vincent Gerusz

  DOI：10.1021/jm301499r

  日期：2013.2.28

  We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial I,PS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 mu g/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.
• Towards Gram-negative antivirulence drugs: New inhibitors of HldE kinase
  作者：Nicolas Desroy、François Moreau、Sophia Briet、Géraldine Le Fralliec、Stephanie Floquet、Lionel Durant、Vanida Vongsouthi、Vincent Gerusz、Alexis Denis、Sonia Escaich

  DOI：10.1016/j.bmc.2008.12.021

  日期：2009.2

  Gram-negative bacteria lacking heptoses in their lipopolysaccharide (LPS) display attenuated virulence and increased sensitivity to human serum and to some antibiotics. Thus inhibition of bacterial heptose synthesis represents an attractive target for the development of new antibacterial agents. HldE is a bifunctional enzyme involved in the synthesis of bacterial heptoses. Development of a biochemical assay suitable for high-throughput screening allowed the discovery of inhibitors 1 and 2 of HldE kinase. Study of the structure-activity relationship of this series of inhibitors led to highly potent compounds. (c) 2008 Elsevier Ltd. All rights reserved.
• New 1,2,4-triazine derivatives and biological applications thereof
  申请人：Mutabilis

  公开号：EP2141164A1

  公开（公告）日：2010-01-06

  The invention relates to new 1,2,4-triazine derivatives of formula (I): wherein A, B, R2 and Y are defined in the application, their preparation and intermediates, their use as drugs and pharmaceutical compositions and associations containing them. The compounds of formula (I) are capable of inhibiting bacterial heptose synthesis.

  这项发明涉及公式(I)的新1,2,4-三嗪衍生物： 其中A、B、R2和Y在申请中有定义， 它们的制备和中间体，它们作为药物和药物组合物的用途以及含有它们的关联物。 公式(I)的化合物能够抑制细菌七糖合成。